Recombinant Human BCHE (C-6His)

产品介绍

{"gui_ge":"10ug","biao_da_su_zhu":"Human Cells","biao_qian":"C-6His","fen_zi_liang":"66.12 KDa","biao_guan_fen_zi_liang":"90 KDa, reducing conditions","xing_tai":"Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 7.5.","chun_du":"Greater than 95% as determined by reducing SDS-PAGE.","nei_du_su_shui_ping":"Less than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.","chu_cun_fang_fa":"Store at ≤-70°C, stable for 6 months after receipt.\nStore at ≤-70°C, stable for 3 months under sterile conditions after opening. \nPlease minimize freeze-thaw cycles. ","yun_shu_tiao_jian":"The product is shipped on dry ice\/polar packs.\nUpon receipt, store it immediately at the temperature listed below.","bei_jing_shuo_ming":"Butyrylcholine Esterase (BCHE) is a secreted protein that belongs to the type-B carboxylesterase\/lipase family. BCHE is a major acetylcholine hydrolyzing enzyme in the circulation. It is detected in blood plasma and present in most cells except erythrocytes. BCHE is an esterase with broad substrate specificity. BCHE can contribute to the inactivation of the neurotransmitter acetylcholine. BCHE can degrade a large number of neurotoxic organophosphate esters. Thus, it plays important pharmacological and toxicological roles and is thought to be involved in the pathological progression. Defects in BCHE are the cause of butyrylcholinesterase deficiency (BChE deficiency) which is a metabolic disorder characterized by prolonged apnoea after the use of certain anesthetic drugs, including the muscle relaxants succinylcholine and other ester local anesthetics."}